KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Receivables Refunds (2016 - 2025)

Historic Receivables Refunds for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $495.1 million.

  • Gsk's Receivables Refunds fell 2127.03% to $495.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $495.1 million, marking a year-over-year decrease of 2127.03%. This contributed to the annual value of $625.1 million for FY2024, which is 3473.05% up from last year.
  • Gsk's Receivables Refunds amounted to $495.1 million in Q3 2025, which was down 2127.03% from $501.6 million recorded in Q2 2025.
  • Gsk's 5-year Receivables Refunds high stood at $952.8 million for Q1 2021, and its period low was $222.7 million during Q1 2022.
  • Moreover, its 5-year median value for Receivables Refunds was $556.7 million (2025), whereas its average is $571.6 million.
  • Per our database at Business Quant, Gsk's Receivables Refunds surged by 10762.95% in 2021 and then tumbled by 7662.29% in 2022.
  • Gsk's Receivables Refunds (Quarter) stood at $655.1 million in 2021, then dropped by 27.49% to $475.0 million in 2022, then fell by 2.54% to $462.9 million in 2023, then skyrocketed by 35.57% to $627.6 million in 2024, then fell by 21.12% to $495.1 million in 2025.
  • Its last three reported values are $495.1 million in Q3 2025, $501.6 million for Q2 2025, and $556.7 million during Q1 2025.